menu search

CANSF / Willow Biosciences forecasts ‘significant' revenue growth in 2023

Willow Biosciences forecasts ‘significant' revenue growth in 2023
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has said it expects to achieve “significant” growth in revenue as well as a “demonstrable” reduction in cash burn for 2023, as steps taken to optimize its business have begun to pay off.  The upbeat outlook accompanied results for the first quarter ended March 31, 2023, which showed revenue of $274,000, up from nil a year earlier. Read More
Posted: May 12 2023, 08:17
Author Name: Proactive Investors
Views: 1106100

CANSF News  

Willow Biosciences and Suanfarma partner to develop large volume anti-infective API through precision fermentation

By Proactive Investors
October 3, 2023

Willow Biosciences and Suanfarma partner to develop large volume anti-infective API through precision fermentation

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has partnered with Spanish life science company Suanfarma to bring sustainably source more_horizontal

Willow Biosciences announces $1.2M debt offering

By Proactive Investors
September 12, 2023

Willow Biosciences announces $1.2M debt offering

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced a non-brokered private placement offering of convertible debenture units, with the goal of ra more_horizontal

Willow Biosciences completes R&D to produce ursodeoxycholic acid

By Proactive Investors
September 6, 2023

Willow Biosciences completes R&D to produce ursodeoxycholic acid

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) said it has successfully completed research and development on its program to produce ursodeoxycholic more_horizontal

Willow Biosciences files patent application for process to produce much cheaper corticosteroids

By Proactive Investors
August 30, 2023

Willow Biosciences files patent application for process to produce much cheaper corticosteroids

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has filed a patent application for a process it has developed to produce corticostero more_horizontal

Willow Biosciences appoints advisor to review opportunities as part of commercial focus on BioOxi platform

By Proactive Investors
August 24, 2023

Willow Biosciences appoints advisor to review opportunities as part of commercial focus on BioOxi platform

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced it has engaged an advisor to assist it with a review of opportunities to enhance value for it more_horizontal

Willow Biosciences shares take off on biopharma manufacturing collaboration announcement

By Proactive Investors
August 21, 2023

Willow Biosciences shares take off on biopharma manufacturing collaboration announcement

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF)' Canadian-listed shares had added more than 23% in the early afternoon on Monday after it announced th more_horizontal

Willow Biosciences announces collaboration with Nasdaq-listed biopharma

By Proactive Investors
August 21, 2023

Willow Biosciences announces collaboration with Nasdaq-listed biopharma

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has announced a collaboration with an unnamed Nasdaq-listed biopharma company to develop new sustainab more_horizontal

Willow Biosciences secures contracts valued at $1M during 2Q

By Proactive Investors
August 9, 2023

Willow Biosciences secures contracts valued at $1M during 2Q

Willow Biosciences told investors that during the second quarter, it closed three new contracts that are expected to bring in more than $1 million in more_horizontal


Search within

Pages Search Results: